NCT05038878View on ClinicalTrials.gov

An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women

PHASE4TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

July 6, 2021

Primary Completion Date

June 24, 2022

Study Completion Date

June 24, 2022

Conditions
Mild Autonomous Cortisol Excess
Interventions
DRUG

Elagolix

Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

AbbVie
All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER